Birociclib Approved for First-Line Indication
China’s First CDK4/6 Inhibitor Covering the Full Spectrum from First- to Late-Line Treatment
Recently, China’s breast cancer treatment landscape has marked another important milestone.
On March 3, the National Medical Products Administration (NMPA) released approval information confirming that Birociclib tablets (brand name: Xuanyue Ning), a CDK4/6 inhibitor independently developed by Xuanzhu Biopharmaceutical, has been approved for a new indication.
The drug is now authorized in combination with aromatase inhibitors (AIs) for the first-line treatment of patients with hormone receptor–positive / human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer.
With this latest approval, Birociclib has become the first and currently the only CDK4/6 inhibitor in China to achieve full coverage across first-line, second-line, and later-line treatment settings for HR+/HER2− advanced breast cancer.
China pharmaceutical wholesaler DengYueMed continues to follow this innovative therapy closely.
Mechanism Optimization of a Next-Generation CDK4/6 Inhibitor
As a next-generation CDK4/6 inhibitor, Birociclib has undergone structural optimization to enhance selectivity for CDK4, while also demonstrating certain inhibitory activity against CDK2.
This mechanistic profile is designed to:
- enhance antitumor efficacy
- maintain a favorable safety profile
- support long-term combination use with endocrine therapy
These characteristics make the therapy suitable for long-term disease management in hormone receptor–positive breast cancer.
Phase III BRIGHT-3 Clinical Results
The newly approved indication is supported by positive results from the Phase III BRIGHT-3 clinical study.
In patients receiving first-line treatment for HR+/HER2− advanced breast cancer, Birociclib combined with letrozole or anastrozole demonstrated significant benefits compared with placebo plus endocrine therapy:
- 47% reduction in the risk of disease progression or death
- Objective response rate (ORR) of 63.5%, compared with 42.5% in the control group
- In patients with liver metastases, a 64% reduction in disease progression risk
These results significantly strengthen Birociclib’s competitiveness in the first-line treatment setting.
Competition in the CDK4/6 Inhibitor Market
Breast cancer remains one of the most prevalent malignancies worldwide, and the therapeutic market continues to expand.
Industry forecasts suggest that by 2030, the global breast cancer therapeutics market may approach USD 70 billion, while the Chinese market is expected to maintain stable growth.
Competition within China’s CDK4/6 inhibitor field is already intense. Approved agents include:
- Dalpiciclib (Hengrui Pharma)
- Abemaciclib (Eli Lilly)
- Ribociclib (Novartis)
- Palbociclib (Pfizer)
Against this competitive landscape, Birociclib’s key differentiation lies in its full treatment-line coverage, providing physicians with a continuous therapy option from first-line through later-line treatment.
NRDL Inclusion Expands Patient Access
Another key milestone occurred in December 2025, when Birociclib was included in China’s National Reimbursement Drug List (NRDL).
This inclusion significantly improves:
- patient accessibility
- affordability of targeted therapy
- potential market penetration
From initial approval in May 2025, to NRDL inclusion, and now to first-line indication expansion, Birociclib’s development trajectory reflects the accelerating pace of innovative drug development in China.
Outlook for Chinese Innovative Oncology Drugs
As clinical data continue to accumulate and treatment indications expand, Chinese-origin innovative medicines are gaining greater visibility in the global oncology market.
China pharmaceutical wholesaler DengYueMed will continue to monitor developments in oncology therapeutics and support international partners in accessing emerging innovative drugs from China.
👉 For a summary of newly approved drugs by the NMPA in February, see:
Full list of NMPA approved drugs – February 2026